Recent Updates
Recently added Catalysts

Roche Holding AG

RHHBYFDA catalysts, PDUFA dates & pipeline intelligence
$60.25
▼ -0.7 · -1.15%

Financials

Last updated
Revenue
R&D Expenses
Operating CF
Total Assets
Total Liabilities
Equity
Shares Out.
D/E Ratio
Quarterly Cash
Unlock full RHHBY financials and dilution scoring
Quarter by quarter figures, cash trend and dilution risk.
Institutional-grade data · Cancel anytime
Volume
2.13 M
Value Traded
128.62 M
Short % Float
-
Days to Cover
1.0

Cash Data

Unlock RHHBY cash position
  • Cash FlowProfitable
  • SEC Filing

Key Stats

Market Cap
-
EPS (TTM)
-
P/E Ratio
-
Ent. Value
-
Total Shares
-
Float Shares
-
Insiders
-
Institutions
-

Upcoming Catalysts

FDA decisions, readouts and PDUFA dates · scored by probability of approval

Catalyst Drug / Treatment Stage Prob. of Approval Description Drug Type Therapeutic Area Source
Unlock every RHHBY catalyst date and PoA score
Every FDA decision, readout and PDUFA date, with drug type, therapeutic area and a PoA score you can trade on.
Institutional-grade data · Cancel anytime
PoA blends historical approval base rates, trial design score and FDA review track record.

RHHBY Catalyst Timeline

Dated clinical, regulatory and corporate events for Roche Holding AG

Unlock the full RHHBY catalyst timeline
Every PDUFA date, readout, approval and corporate move, tiered by market impact and updated daily.
Institutional-grade data · Cancel anytime

Past FDA Catalysts and PDUFA Decisions

How RHHBY actually traded into and out of each decision

Date Drug Catalyst Stage Reaction Event Move % Best Trade %
2026-10-15Enspryng (satralizumab) PDUFA Date ApprovedPDUFA
Unlock 14 more RHHBY historical catalysts
Institutional-grade data · Cancel anytime
Reaction: 30 trading days around the event · Event Move: close to close on decision day · Best Trade: peak run-up from entry 10 days before the decision

Drug Pipeline Intelligence

Pipeline Score
Pipeline Value
Valuation Signal
114
Drugs Scored
rNPV / MCap
Top Drug
Top 2%
Large Pharma
(rank 15 of 725)
Percentile Rank
Showing 88 of 886 assets
DrugIndicationPhasePTRSrNPVStatusEnrollVelocityDesignEst. CompletionML SignalLast Change
Enicepatide PeptidesNCT07351058Obesity or OverweightPhase 3 RECRUITING 3,600Aug 7, 2028
Enicepatide PeptidesNCT07889648Type 2 Diabetes MellitusPhase 3 NOT YET_RECRUITING 948Apr 23, 2029
Enicepatide PeptidesNCT07918846OverweightPhase 3 NOT YET_RECRUITING 8,200Apr 17, 2031
Tifeglipron Small MoleculesNCT07112872Type 2 Diabetes MellitusPhase 2 RECRUITING 330Feb 5, 2028
RO7795081 Small MoleculesNCT06982131OverweightPhase 1 ACTIVE NOT_RECRUITING 40Dec 7, 2026
RO7795081 Small MoleculesNCT07499050Overweight or ObesityPhase 1 ACTIVE NOT_RECRUITING 30Jan 9, 2027
RO7795081 Small MoleculesNCT07741604Renal ImpairmentPhase 1 RECRUITING 60Feb 1, 2028
Fenebrutinib Small MoleculesNCT07937852Multiple SclerosisPhase 3 NOT YET_RECRUITING 1,800Nov 30, 2029
Fenebrutinib Small MoleculesNCT04544449Multiple Sclerosis, Primary ProgressivePhase 3 ACTIVE NOT_RECRUITING 985Jul 21, 2027
Fenebrutinib Small MoleculesNCT05119569Relapsing Multiple SclerosisPhase 3 ACTIVE NOT_RECRUITING 1,618Jun 30, 2027
Divarasib Small MoleculesNCT04449874Non-Small Cell Lung CancerPhase 3 ACTIVE NOT_RECRUITING 2,156Dec 31, 2027
Giredestrant Small MoleculesNCT04576455Estrogen Receptor-Positive, HER2-Negative Locally Advanced or Metastatic Breast CancerPhase 3 ACTIVE NOT_RECRUITING 1,295Aug 25, 2027
Giredestrant Small MoleculesNCT04961996Early Breast CancerPhase 3 ACTIVE NOT_RECRUITING 6,191Sep 30, 2033
Giredestrant Small MoleculesNCT05306340Estrogen Receptor (ER)-Positive, HER2-negative, Locally Advanced or Metastatic Breast CancerPhase 3 ACTIVE NOT_RECRUITING 373Jun 15, 2027
Giredestrant Small MoleculesNCT06065748Estrogen Receptor-Positive, HER2-Negative Advanced Breast CancerPhase 3 ACTIVE NOT_RECRUITING 1,050Feb 12, 2029
Giredestrant Small MoleculesNCT04802759Inoperable, Locally Advanced or Metastatic, ER-positive Breast CancerPhase 1/2 RECRUITING 316May 30, 2029
Giredestrant Small MoleculesNCT03332797Breast CancerPhase 1 ACTIVE NOT_RECRUITING 256Jul 31, 2027
Cevostamab BiologicsNCT06934044Multiple MyelomaPhase 3 ACTIVE NOT_RECRUITING 1,366Nov 15, 2028
Cevostamab BiologicsNCT07629583Lupus Erythematosus, SystemicPhase 1 RECRUITING 46Mar 29, 2030
Cevostamab BiologicsNCT05927571Relapsed or Refractory Multiple MyelomaPhase 1 RECRUITING 120Jul 31, 2027
Ipatasertib Small MoleculesNCT04931342Ovarian CancerPhase 2 ACTIVE NOT_RECRUITING 176May 30, 2028
Astegolimab BiologicsNCT05878769Chronic Obstructive Pulmonary DiseasePhase 3 ACTIVE NOT_RECRUITING 4,714Jun 30, 2027
RO7204239 Small MoleculesNCT06965413ObesityPhase 2 ACTIVE NOT_RECRUITING 285Mar 31, 2027
RO7204239 Small MoleculesNCT07137585Type 2 Diabetes MellitusPhase 1 ACTIVE NOT_RECRUITING 30Feb 28, 2027
Sefaxersen RNA-Based TherapiesNCT05797610Primary IgA NephropathyPhase 3 ACTIVE NOT_RECRUITING 459Aug 31, 2029
Unlock the RHHBY pipeline intelligence model
PTRS, rNPV, enrollment velocity, trial design quality and ML risk signals for every asset above.
Institutional-grade data · Cancel anytime

Clinical Trial Results

Readouts, endpoints and source filings for every RHHBY program

Drug Name Indication Phase Date Trial Results SummaryTitleSource
Scroll for more · summaries link to the source press release
Unlock every RHHBY trial readout
Institutional-grade data · Cancel anytime

Inside Trades

Unlock RHHBY insider buying and selling
Monthly insider buys and sells against the stock price, with the insider sentiment reading.
Institutional-grade data · Cancel anytime
InsiderSideSharesPriceValueDate
No insider trades match the selected filters.
Unlock the full RHHBY insider trade log
Institutional-grade data · Cancel anytime

Hedge Fund 13F Activity

Fund % of Portfolio Current MV Shares Owned Activity
Sofinnova Investments, Inc. 4.1 % 70.76 M 1.37 M
Unlock every fund holding RHHBY
Every 13F position with quarter over quarter share flow and average entry price.
Institutional-grade data · Cancel anytime
Unlock hedge fund flows in RHHBY
Shares held by hedge funds each quarter, and who bought or sold.

Ownership Trends

Sign in to see RHHBY ownership
Insider and institutional ownership, quarter by quarter.

RHHBY Short Interest

Shares sold short, counted twice a month.

-
Short % of Float
of tradable shares sold short
2.9M
Shares Sold Short
+5.2% vs prior count
1.0 Low
Days to Cover
trading days of normal volume to buy every short share back
3.0M
Avg Daily Volume
the average used for days to cover
Unlock RHHBY short interest history
Two years of days to cover and shares sold short, with every count and its change.
Institutional-grade data · Cancel anytime

Options Data

Option Volume

Open Interest
Call OI
Put OI
Put-Call Ratio
OI 30-day avg
Today vs avg
Option Volume
Call Vol
Put Vol
Put-Call Ratio
Vol 30-day avg
Today vs avg

Option Chain Statistics

ExpiryCall VolPut VolVol P/CCall OIPut OIOI P/CIV CallIV Call OI-WtdIV Call Vol-WtdIV PutIV Put OI-WtdIV Put Vol-Wtd
Unlock RHHBY option chain statistics
Per-expiry call and put volume, open interest, put-call ratios and implied volatility.
Institutional-grade data · Cancel anytime

Real-Time Option Chain

CallsStrikePuts
LastVolOILastVolOI
No data available
Unlock the live RHHBY option chain
Live calls and puts by strike: last price, volume and open interest for every expiry.
Institutional-grade data · Cancel anytime

Calls vs Puts by Expiry

CallsPutsLog scale
Unlock RHHBY options analytics
Institutional-grade data · Cancel anytime

Competitive positioning

How RHHBY ranks across every disease it competes in

Competitive Position is a premium feature
See how RHHBY ranks against every competitor across each disease it develops in: phase, best drug, trials and likelihood of approval.
Start free trial

RHHBY News

About Roche Holding AG

BIOPHARMAWATCH ELITE
Trade the next RHHBY catalyst before the market reprices
Every FDA decision, PoA score, 13F move and dilution flag on this page, for 1,100+ biotech tickers. From $24/mo billed annually.
Cancel anytime